Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 35,419 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Squamous Cell Carcinoma, Skin Cancer, Keratoacanthoma, Cutaneous Tumor, Skin Cancer, Squamous Cell, Lesion Skin
Interventions: Injection of TVEC into target lesions - week 1-2, Injection of TVEC into target lesions 3wks after 1st injection, Injection of TVEC into target lesions 2wks after 2nd injection, Injection of TVEC into target lesions 2wks after 3rd injection; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Scottsdale, Arizona • Tucson, Arizona

Conditions: Healthy Participants, Dyslipidemia
Interventions: AZD4954, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more

Conditions: Infections, Respiratory, Diarrhea
Interventions: probiotic strain Bb-12, no Bb-12; Other
Lead sponsor: Georgetown University; Other
Eligibility: 2 Years to 4 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Solid Tumors
Interventions: CP-870,893; Biological
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Schizophrenia
Interventions: AZD8529, Placebo to match AZD8529; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV-1
Interventions: CMV/HIV-CAR T Cells; Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Duarte, California • San Diego, California

Conditions: Obesity, Overweight
Interventions: Confident Moves (CM) Intervention; Behavioral
Lead sponsor: Iowa State University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Cardiovascular Diseases
Interventions: HEARTS, PF; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 30 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Lumbar Degenerative Disc Disease, Lumbar Spinal Stenosis, Lumbar Spondylolisthesis, Lumbar Spinal Deformity, Lumbar Spondylosis
Interventions: Interbody cage (titanium), Interbody cage (PEEK); Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer
Interventions: Enzalutamide, exemestane, Placebo (for enzalutamide); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 89
States / cities: Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more

Conditions: ADHD, Sleep
Interventions: Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-C); Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 13 Years to 17 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Myopia
Interventions: Single Vision Contact Lens, Multifocal Contact Lens 1, Multifocal Contact Lens 2; Device
Lead sponsor: University of Houston; Other
Eligibility: 18 Years to 39 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stargardt Disease
Interventions: Emixustat, Placebo; Drug
Lead sponsor: Kubota Vision Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 11
States / cities: Beverly Hills, California • San Francisco, California • Atlanta, Georgia + 8 more

Conditions: Parkinson's Disease
Interventions: MEDI1341, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Sickle Cell Disease (SCD)
Interventions: Crizanlizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 9 more

Conditions: Traumatic Brain Injury (TBI) Patients, Severe Traumatic Brain Injury
Interventions: SeeMe Multimodal Auditory Command Protocol; Diagnostic Test
Lead sponsor: Stony Brook University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Human Papillomavirus (HPV)
Interventions: Provider assessment and feedback, Provider reminders, Provider education, Patient reminders, Parent education; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 11 Years to 17 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant Neoplasm, Metastatic Skin Squamous Cell Carcinoma, Metastatic Small Intestinal Adenocarcinoma, Rare Neoplastic Syndrome, Refractory Malignant Neoplasm, Stage IV Small Intestinal Adenocarcinoma AJCC v8, Unresectable Malignant Neoplasm
Interventions: Atezolizumab, Cobimetinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Subjects
Interventions: Glepaglutide; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pancreatic Ductal Adenocarcinoma (mPDAC)
Interventions: Cemiplimab Plus Gemcitabine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy Elderly Volunteers
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years to 80 Years · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Migraine, With or Without Aura
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 50
States / cities: Mobile, Alabama • Glendale, Arizona • Rogers, Arkansas + 44 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Plasma Cell Neoplasms, Lymphoma, Hodgkin's Disease, Aplastic Anemia
Interventions: Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide, Mycophenolate Mofetil (MMF), Tacrolimus, Hematopoietic stem cell transplantation (HSCT); Radiation · Biological · Drug + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid-Related Disorders
Interventions: OD prevention/response training, OD prevention/response training + PI mobile application; Behavioral
Lead sponsor: National Development and Research Institutes, Inc.; Other
Eligibility: 18 Years to 29 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Study of TVEC in Patients With Cutaneous Squamous Cell Cancer

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Yogurt Study in Children 2-4 Years Old Attending Daycare

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS

Confident Moves Intervention Efficacy Trial: Obesity Care Settings

Cardiovascular Disease Multimorbidity

Lumbar Fusion With Nexxt Spine 3D-Printed Titanium Interbody Cages

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Treating Sleep in Teens With ADHD

Evaluation of Visual Performance With Contact Lenses

Safety and Efficacy of Emixustat in Stargardt Disease

Single Ascending Dose Study of MEDI1341 in Healthy Volunteers

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

SeeMe: Using Automated Facial Tracking to Detect Voluntary Behavior in Brain Injury

Multi-component Interventions to Increase HPV Vaccination in a Network of Pediatric Clinics

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

Safety and Efficacy in Adult Subjects With Acute Migraines

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Mobile Intervention for Young Opioid Users